Drug Type Monoclonal antibody |
Synonyms HLX 55, KTN-0216, KTN0216 |
Target |
Mechanism c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | TW | 03 Mar 2020 | |
Liver Cancer | IND Approval | CN | 10 Aug 2019 | |
Lung Cancer | IND Approval | CN | 10 Aug 2019 | |
Stomach Cancer | IND Approval | CN | 10 Aug 2019 | |
Glioblastoma | Preclinical | CN | 13 Dec 2018 |